Trial Profile
A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Tislelizumab (Primary)
- Indications Colorectal cancer; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Registrational; Therapeutic Use
- Acronyms RATIONALE 209
- Sponsors BeiGene
- 24 Oct 2023 Results of updated analysis of longer follow up presented at the 48th European Society for Medical Oncology Congress
- 13 Dec 2022 Planned number of patients changed from 80 to 200.
- 13 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Sep 2027.